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Abstract
Background Multimorbidity increases healthcare resource utilization. Little is known on specific comorbidity combinations.
Aims To identify comorbidities associated with increased resource utilization among inpatients admitted for gastrointestinal 
bleeding (GIB).
Methods This retrospective cross-sectional study, 1/2010–5/2018 at the University Hospital Zurich, Switzerland, analyzed 
electronic health records of patients with upper (UGIB) and lower (LGIB) GIB, focusing on length of stay (LOS) and 30-day 
readmissions for resource use and clinical outcomes, investigated by multivariable regression adjusted for antithrombotics.
Results Of 1101 patients, 791 had UGIB and 310 LGIB, most often melena and bleeding diverticula, respectively. In UGIB, 
thromboembolic events showed a trend toward 27% increased LOS (1.27; 95% confidence interval [CI] 1.00–1.61), antithrom-
botics independently associated with 46% increased LOS (1.46; 95% CI 1.32–1.62). Cancer (odds ratio [OR] 2.86; 95% CI 
1.68–4.88) independently associated with 30-day readmissions, anemia showed a trend (OR 1.68; 95% CI 1.00–2.84). In 
LGIB, none of the investigated comorbidities associated with increased LOS, but antithrombotics independently associated 
with 25% increased LOS (1.25; 95% CI 1.07–1.46). Atrial fibrillation/flutter (OR 2.69; 95% CI 1.06–6.82) and cancer (OR 
4.76; 95% CI 1.40–16.20) associated strongly with 30-day readmissions.
Conclusions In both groups, cancer associated with 30-day readmissions, antithrombotics with increased LOS. Thrombo-
embolic events and anemia showed clinically important trends in UGIB. Atrial fibrillation/flutter associated with 30-day 
readmissions in LGIB. Prospective studies are needed to investigate these complex multimorbid populations and establish 
appropriate guidelines.
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Introduction
The aging population of patients with multiple concomitant 
acute and chronic conditions is growing [1]. An increasing 
proportion of patients is considered multimorbid due to the 
effects of progressive deterioration in conditions often relat-
ing to the heart, kidney and liver [2]. Van den Akker and 
colleagues [3] specified multimorbidity as the simultaneous 
presence of two or more chronic diseases. However, the need 
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for a standardized definition is advocated [4]. More recent 
approaches emphasize the characterization of multimorbid-
ity in terms of the complexity of disease combinations [5]. 
For instance, people over 64 years of age with dementia have 
a significantly higher number of comorbidities (most often 
diabetes or other cardiovascular diseases like hypertension) 
than people who are not diagnosed with this index disease 
[6].
The WHO estimates the average life expectancy of Euro-
peans at 77.5 years [7]. With improving control of chronic 
diseases, both life expectancy and numbers of multimorbid 
patients will increase further [8]. Multimorbidity is also the 
rule rather than the exception in Switzerland, both in hos-
pital and especially in general medicine, and it increases 
with age [9].
Medical and socio-economic healthcare needs are 
expected to be a major task within the next decades [10]. 
However, disease outbreaks such as the coronavirus disease 
2019 (COVID-19), which is especially threatening to multi-
morbid patients, add new challenges to the existing burdens 
on the healthcare system [11]. A part of the risk assessment 
for the management of multimorbid patients is the consider-
ation of risk factors associated with worse clinical outcomes 
in order to improve further resource planning and monitor-
ing. Hospital length of stay (LOS) and 30-day readmissions 
represent important clinical outcomes with implications for 
healthcare utilization and costs. For instance, a recent study 
has shown that ancillary depression in multimorbid inpa-
tients is associated with increased LOS and 30-day readmis-
sions [12].
The present study investigated inpatients at a Swiss ter-
tiary care medical center who were hospitalized for the 
treatment of acute gastrointestinal bleeding (GIB). GIB 
requires frequent hospitalizations with esophageal varices, 
peptic ulcer disease, esophagitis and gastritis as most com-
mon causes for upper gastrointestinal bleeding (UGIB) [13] 
and diverticular bleeding for lower gastrointestinal bleeding 
(LGIB) [14].
GIB is associated with a burden of disease, with UGIB 
having a reported mortality of 2–10% [15], and LGIB—
although less frequent—a mortality of 10–20% [16]. The 
objective of this study was to determine whether UGIB or 
LGIB was associated with the two important clinical out-
comes, increased LOS and 30-day readmissions depending 
on clinically significant comorbidities.
Thus, the purpose of our study was to:
(a) describe and characterize a large inpatient population 
admitted for the treatment of acute GIB, stratified by 
UGIB vs LGIB, and
(b) to investigate comorbid conditions in UGIB vs LGIB 




We conducted a retrospective, cross-sectional study using 
electronic health record (EHR) data and considered eli-
gible inpatients hospitalized at the University Hospital 
Zurich between January 1, 2010, and May 31, 2018 (total 
of 273,378 inpatient stays). All EHR data used in this study 
were routinely collected. We followed the STrengthening 
the Reporting of OBservational studies in Epidemiology 
(STROBE) guidelines [17].
Ethical Considerations
Ethics approval was obtained from the Cantonal Ethics 
Commission Zurich, BASEC 2016-00525, which waived 
the requirement for obtaining informed consent for this ret-
rospective study.
Setting
The University Hospital Zurich is a large tertiary care aca-
demic medical center in Zurich, Switzerland. The institution 
has approximately 900 beds and cares for more than 35,000 
inpatients per year. Over 8200 employees work at this hos-
pital, covering all specialties except orthopedic surgery and 
pediatrics.
Inclusion and Exclusion Criteria
The reason for hospitalization was the primary diagnosis, 
flagged as such in the EHR. All diagnoses were ICD-10 
coded (ICD: International Classification of Diseases, WHO, 
Geneva, Switzerland). The ICD-10 coded primary diagnoses 
were used to identify our population of interest: patients 
admitted for the treatment of acute GIB. Iterative literature 
searches were alternated with research group discussions 
to reach consensus about the ICD-10 codes that referred 
to these patients. The same process was used to define the 
ICD-10 codes for the identification of clinically relevant 
comorbidities among secondary diagnoses. After the study 
population was identified, detailed chart reviews were con-
ducted to clarify any case of ambiguity: For instance, the 
diagnoses sometimes indicated that a patient suffered from 
both UGIB and LGIB. Therefore, the ICD-10 code K92.2 
(gastrointestinal hemorrhage) was verified by chart review 
as UGIB; except for 7 cases, which were excluded due to 
concurrent diagnoses indicating LGIB (i.e., hemorrhoids, 
diverticulitis and diverticulosis with bleeding). The ICD-
10 code K92.1 (melena) was allocated to UGIB [18]. If 
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potential subjects had a record that indicated refusal to be 
involved in research, they were excluded from the study. 
Patients with incomplete information on potential readmis-
sion events (patients discharged within 29 days before end 
of study period) and patients who died during their stay were 
also excluded (n = 59).
Definition and Classification of Gastrointestinal 
Bleeding
We used ICD-10 coded diagnoses to identify patients with 
acute GIB and stratified them into two study groups.
 I. UGIB: I85.0, I98.3, K22.3, K22.6, K22.8, K25.0, 
K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, 
K27.0, K27.2, K27.4, K27.6, K28.0, K28.4, K28.6, 
K29.0, K31.82, K92.0, K92.1 and K92.2
   and
 II. LGIB: K55.22, K55.82, K57.01, K57.03, K57.11, 
K57.13, K57.31, K57.41, K57.51, K57.91, K57.93, 
K62.5, K64.0, K64.1, K64.2, K64.3 and K64.9
Outcomes and Measures
The outcome variables investigated were LOS and 30-day 
all-cause readmissions, the latter defined as any admission 
within 30 days of the index admission. The predefined expo-
sure of interest variable was presence of 15 comorbid condi-
tions potentially associated with increased LOS or 30-day 
readmissions (cf. section Co-Variables, below). We strictly 
differentiated between UGIB and LGIB.
We used the natural logarithm to transform the skewed 
outcome variable LOS, as we did previously (described in 
more detail elsewhere [12]). This allowed the application of 
linear regression models. The estimated coefficients were 
back-transformed by raising e to the power of the coeffi-
cients, and these results can be interpreted as percentage 
increases or decreases.
Co‑variables
Co-variables were considered according to a list of diseases 
with clinical relevance, using the bleeding risk score termed 
HAS-BLED Score [19] and the stroke risk categorization 
schema CHA2DS2-VASCc-Score [20]. The 15 comorbidi-
ties were identified among all secondary diagnoses which 
were comprehensively ICD-10 coded. The physicians in 
charge of the patients defined and updated the primary diag-
nosis and all secondary diagnoses over the course of the hos-
pital stay. After the patients discharge, professional medical 
coders assigned ICD-10 codes to each diagnosis. Four condi-
tions were based on the ICD-10 coded Elixhauser Comor-
bidity Index definitions by Quan et al. [21]: anemia (blood 
loss and iron deficiency), cancer (solid tumor with/without 
metastasis), coagulopathy (purpura and other hemorrhagic 
diatheses) and chronic pulmonary diseases. The other 11 
conditions (i.e., alcohol use disorders, atrial fibrillation or 
flutter, chronic kidney disease, depression, diabetes mel-
litus, heart failure, heart valve disease, hypertension, liver 
disease, thromboembolic event and vascular disease) were 
defined by means of iterative literature searches alternated 
with research group discussions to reach consensus. Throm-
boembolic event includes the diagnoses pulmonary embo-
lism and deep vein thrombosis. Vascular disease was defined 
by the diagnoses of acute myocardial infarction, coronary 
heart disease, chronic ischemic heart disease and peripheral 
arterial vascular disease. The comprehensive lists with their 
specific ICD-10 codes are summarized in Supplementary 
Table S1. Multimorbidity was defined as the presence of at 
least two diagnoses [22]. We controlled for multimorbidity 
and burden of disease by adjusting for diagnosis count [23].
To control for potential confounding in the context of the 
therapeutic conflict of reinstating antithrombotic medication 
for our inpatients admitted with acute GIB, comprehensive 
drug ordering data were extracted. Antithrombotic agents 
were identified by the Anatomical Therapeutic Chemical 
Classification System (ATC, World Health Organization, 
Geneva, Switzerland) class B01A of which the following 
categories of drugs were ordered at least once for the inpa-
tients studied: vitamin K antagonists (ATC class B01AA), 
heparin (ATC class B01AB), platelet aggregation inhibi-
tors excluding heparin (ATC class B01AC) and direct factor 
Xa inhibitors (ATC class B01AF). All drug prescriptions 
including “free-text” orders were part of the data analysis: 
We (i) manually mapped the most frequent orders lack-
ing ATC information to the correct ATC code, (ii) used an 
automated character sequence comparison algorithm to map 
the same ATC code to similar orders and (iii) reviewed the 
automated mappings and revised where necessary. These 
steps were repeated several times to augment and improve 
our mapping table.
Data Processing and Statistics
Descriptive statistics of all measures were generated with 
median and interquartile ranges for continuous variables 
with a non-parametric distribution. For categorical vari-
ables, numbers and percentages of the total are reported. 
We conducted comparative statistical analyses to describe 
patients with UGIB vs LGIB using chi-squared tests for cat-
egorical variables and Mann–Whitney U tests for continuous 
variables. For all patients with UGIB and LGIB, we used 
multivariable linear and logistic regression models to test 
whether the 15 conditions were independently associated 
with longer LOS and 30-day readmissions, respectively. All 
models were adjusted for age, sex, diagnosis count, year of 
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discharge, the 15 comorbidities, and orders of antithrom-
botic medications. We additionally controlled for LOS in 
our 30-day readmission models. For the statistical analyses, 
the software R, version 3.6.1 (R Foundation for Statistical 
Computing, Vienna, Austria) was used. A p value of ≤ 0.05 
was considered as significant.
Results
A total of 1101 patients admitted for the treatment of acute 
GIB were identified, and two-thirds of them were male 
(Table 1). The proportions of patients with UGIB and LGIB 
were 72% and 28%, respectively. The UGIB population was 
significantly younger (median 65 years) than the patients 
with LGIB (median 71 years). All included patients were 
multimorbid. Regarding comorbidities, the proportions of 
patients with vascular disease, alcohol use disorder, atrial 
fibrillation/flutter, cancer and liver disease differed signifi-
cantly between the study groups. A total of 671 patients 
(61%) received antithrombotic medications for the preven-
tion of thromboembolic and cardiovascular events. Over the 
course of their stays, 10% of all patients admitted for the 
treatment of acute GIB received vitamin K antagonists, 44% 
heparin, 31% had platelet aggregation inhibitors, and < 3% 
received direct factor Xa inhibitors. The median length of 
stay was 6 days for UGIB compared with 5 days for LGIB. 
Overall, 17% of all patients with GIB were readmitted to our 
institution within 30 days after discharge.
UGIB patients were most often admitted for melena, 
whereas bleeding diverticula were the predominant reason 
for admission among LGIB patients (Table 2).
Analysis of Associations with LOS Among UGIB 
Patients
LOS appeared to increase by 10% per additional diagnosis 
in UGIB patients (Table 3). Thromboembolic events showed 
a clinically important trend toward increased LOS which 
almost reached statistical significance. Antithrombotic 
agents were independently associated with 46% longer LOS.
Analysis of Associations with 30‑Day Readmissions 
Among UGIB Patients
Patients were more likely of having a 30-day readmission 
with increasing year during the study period (Table 3). 
Cancer was the only comorbidity statistically significantly 
associated with a 30-day readmission, with an odds ratio 
almost three times as high as for UGIB patients without 
cancer. Clinically important trends toward 30-day readmis-
sions were observed for patients with hypertension, diabe-
tes, chronic kidney disease, chronic obstructive pulmonary 
disease (COPD) and finally anemia the only one nearly 
reaching statistical significance.
Analysis of Associations with LOS Among LGIB 
Patients
None of the investigated comorbidities were associated with 
an increased LOS. However, older patients stayed longer in 
the hospital and patients seemed to stay almost 10% longer 
per additional diagnosis. Heart valve disease and vascular 
disease were statistically significantly associated with a 
shorter LOS (Table 4). Antithrombotic agents were inde-
pendently associated with a 25% increased LOS.
Analysis of Associations with 30‑Day Readmissions 
Among LGIB Patients
Atrial fibrillation/flutter and cancer were independently 
associated with 30-day readmissions with nearly three and 
nearly five times increased odds ratios, respectively. Poten-
tially important trends toward 30-day readmissions were 
observed for patients with anemia, alcohol use disorders, 
vascular disease and also for patients on anticoagulants; 
however, none of those close to statistical significance 
(Table 4).
Discussion
In this retrospective study of 1101 patients admitted for the 
treatment of GIB, we found higher presentation of UGIB 
compared to LGIB among patients with a multimorbid-
ity profile. While thromboembolic events only showed a 
clinically important trend toward increased LOS in patients 
with UGIB, antithrombotic agents statistically signifi-
cantly associated with increased LOS. Among patients with 
LGIB, none of the comorbidities investigated were associ-
ated with increased LOS; however, atrial fibrillation/flutter 
was strongly associated with 30-day readmissions. Cancer 
showed strong independent associations with 30-day read-
missions in both, UGIB and LGIB. The present investigation 
revealed a relatively high 30-day readmission rate of 18.1% 
among patients with UGIB versus 14.5% among LGIB 
patients. We further found multimorbidity, i.e., the burden 
of disease considered by diagnosis count, to be an important 
independent reason for a prolongation of LOS. LOS seemed 
to increase by approximately 10% per additional diagnosis 
for both groups.
GIB is common [24, 25]. Clinical symptoms range from 
anemia to fulminant bleeding with shock. Management 
requires a differentiated approach from the first sign of GIB, 
during acute care and for the prevention of recurrent bleed-
ing. Multimorbidity increases the complexity of patient care 
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for several reasons. Treatment pathways developed for the 
best care of a single disease may interfere with an algorithm 
developed for another, co-existing disease (disease-disease 
interaction) [26]. In a Swiss cross-sectional study with 
patients admitted to an emergency outpatient department, 
every second patient showed therapeutic conflicts between 
Table 1  Baseline characteristics
A list of 15 comorbidities was defined according to ICD-10 diagnosis codes. The following diagnoses were based on the Elixhauser Comorbidity 
Index [21]: anemia, cancer, coagulopathy and chronic pulmonary diseases. Patients who died in hospital were excluded
* Treatment-relevant diseases according to HAS-BLED Score or  CHA2DS2-VASCc-Score
a HAS-BLED Score
b CHA2DS2-VASCc-Score




Age, median years [IQR] 65.0 [52.0, 75.0] 71.00 [61.0, 79.0] < 0.001 67.0 [54.0, 76.0]
Male sex, n (%) 519 (65.6) 199 (64.2) 0.708 718 (65.2)
Marital status 0.181
 Married/partnered (4) 418 (52.8) 165 (53.2) 583 (53.0)
 Widowed/divorced/separated (3) 204 (25.8) 92 (29.7) 296 (26.9)
 Single (2) 144 (18.2) 41 (13.2) 185 (16.8)
 Other/unknown (1) 25 (3.2) 12 (3.9) 37 (3.4)
Number of diagnoses, median [IQR] 9.0 [6.0, 13.0] 9.00 [5.0, 13.0] 0.941 9.00 [6.0, 13.0]
 ≥ 2 ICD-10 codes 42 (5.3) 30 (9.7) 72 (6.5)
 3–5 ICD-10 codes 140 (17.7) 52 (16.8) 192 (17.4)
 6–9 ICD-10 codes 255 (32.2) 81 (26.1) 336 (30.5)
 ≥ 10 ICD-10 codes 354 (44.8) 147 (47.4) 501 (45.5)
Comorbidities* n (%)
Hypertensiona,b 239 (30.2) 108 (34.8) 0.158 347 (31.5)
Vascular  diseaseb 199 (25.2) 111 (35.8) 0.001 310 (28.2)
Alcohol use  disordersa 248 (31.4) 25 (8.1) < 0.001 273 (24.8)
Coagulopathy 156 (19.7) 70 (22.6) 0.33 226 (20.5)
Chronic kidney  diseasea 152 (19.2) 71 (22.9) 0.199 223 (20.3)
Diabetes  mellitusb 152 (19.2) 71 (22.9) 0.199 223 (20.3)
Atrial fibrillation/flutter 104 (13.1) 68 (21.9)  < 0.001 172 (15.6)
Anemia 104 (13.1) 49 (15.8) 0.294 153 (13.9)
Cancer 94 (11.9) 19 (6.1) 0.007 113 (10.3)
Valvular heart  diseaseb 61 (7.7) 35 (11.3) 0.076 96 (8.7)
Liver  diseasea 79 (10.0) 12 (3.9) 0.001 91 (8.3)
Chronic pulmonary disease 57 (7.2) 28 (9.0) 0.37 85 (7.7)
Heart failure/insufficiencyb 48 (6.1) 22 (7.1) 0.623 70 (6.4)
Depression 34 (4.3) 11 (3.5) 0.692 45 (4.1)
Thromboembolic  eventb 29 (3.7) 6 (1.9) 0.2 35 (3.2)
Antithrombotic agents 468 (59.2) 203 (65.5) 0.062 671 (60.9)
Vitamin K antagonists (ATC B01AA) 75 (9.5) 39 (12.6) 0.159 114 (10.4)
Heparin group (ATC B01AB) 345 (43.6) 138 (44.5) 0.839 483 (43.9)
Platelet aggregation inhibitors excl. Heparin 
(ATC B01AC)
231 (29.2) 110 (35.5) 0.051 341 (31.0)
Direct factor Xa inhibitors (ATC B01AF) 16 (2.0) 12 (3.9) 0.124 28 (2.5)
Outcomes
Length of stay in days, median [IQR] 6.0 [4.0, 10.0] 5.00 [4.0, 9.0] 0.378 6.0 [4.0, 10.0]
30-day readmission, n (%) 143 (18.1) 45 (14.5) 0.186 188 (17.1)
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the disease and co-existing medication (drug-disease inter-
action) [27]. One in three of these interactions was serious, 
possibly leading to life-threatening therapeutic conflicts. 
Therapeutic conflicts are common among multimorbid 
patients and merit further research. Management has, how-
ever, become more challenging regarding antithrombotic 
therapy for patients with GIB [28]. The use of antithrombot-
ics in daily clinical practice is indicated for the reduction of 
the thromboembolic risk, while increasing the risk of bleed-
ing. Antiplatelet medication should be paused depending 
on the severity of bleeding [29]. However, after endoscopic 
control of bleeding, medication should be reinstated as soon 
as possible. The timing should consider the individual car-
diovascular risk. Therefore, interdisciplinary work seems to 
be of particular importance for the management of multi-
morbid patients with GIB.
In our LGIB patients, atrial fibrillation was associated 
with an increased risk of 30-day readmissions. As expected, 
atrial fibrillation is a critical comorbidity requiring a balance 
between stroke and bleeding risk in decisions on thrombo-
sis prophylaxis [30]. As shown in the ARISTOTLE trial, a 
history of GIB (especially recent GIB) was associated with 
increased risk of subsequent, severe GIB in anticoagulated 
patients with atrial fibrillation [31]. A study conducted in 
the USA on hospitalized adult patients with atrial fibrilla-
tion conducted a cost analysis in relation to occurrence of 
hospital-associated bleeding events [32]. Results showed 
that hospital-associated bleedings (n = 2991) was attributed 
to an estimated 8106 additional hospital days and $16.4 mil-
lion costs compared with non-bleeders. As indicated by this 
cost analysis in atrial fibrillation, the economic burden is 
closely associated with the management of such multimor-
bid patients. In addition to functional limitations, reduced 
quality of life and increasing mortality, it has been shown 
that multimorbidity is associated with high utilization of 
health services and the resulting costs [33]. As another study 
demonstrated, an increasing number of risk factors was asso-
ciated with longer LOS and higher costs [34]. In comparison 
with other studies, length of stay for GIB was similar to our 
study [35].
In a prospective study of cancer patients, researchers 
found an inverse relationship with clinically relevant bleed-
ing during and after hospital stay, therefore recommend-
ing further context-specific research [36]. The authors 
pointed out a therapeutic challenge in the case of cancer 
patients. After discharge, the risk of bleeding in absence 
Table 2  Inpatients admitted for the treatment of acute gastrointestinal bleeding (GIB) according to upper and lower GIB
Source of the event according to the ICD-10-code Description n (%)
Upper gastrointestinal bleeding
K92.1 Melena 174 (15.9)
K92.2 Gastrointestinal hemorrhage 160 (14.5)
K26.0, K26.2 Acute duodenal ulcer with hemorrhage, w/o perforation 89 (8.1)
K26.4, K26.6 Chronic or unspecified duodenal ulcer with hemorrhage, w/o perforation 83 (7.5)
K25.0, K25.2 Acute gastric ulcer with hemorrhage (Ulcus ventriculi), w/o perforation 68 (6.2)
K25.4, K25.6 Chronic or unspecified gastric ulcer with hemorrhage, w/o perforation 67 (6.1)
K92.0 Hematemesis 57 (5.2)
K22.6 Gastro-esophageal laceration-hemorrhage syndrome (i.e., Mallory-Weiss 
syndrome)
49 (4.5)
K22.8 Disorders of esophagus (e.g., esophageal bleeding) 46 (4.2)
K31.82 Angiodysplasia of the stomach and duodenum with bleeding (e.g., Dieulafoy’s 
lesion)
44 (4.0)
K29.0 Acute hemorrhagic gastritis 28 (2.5)
K22.3 Perforation of esophagus 26 (2.4)
I98.3, I85.0 Esophageal varices with bleeding 23 (2.1)
K27.4, K27.6, K28.4, K28.6 Chronic or unspecified peptic or gastrojejunal ulcer with hemorrhage, w/o 
perforation
12 (1.1)
K27.0, K27.2, K28.0, K28.4 Acute peptic or gastrojejunal ulcer with hemorrhage, w/o perforation 9 (0.8)
Lower gastrointestinal bleeding
K57.01, K57.11, K57.31, K57.41, K57.51, K57.91 Diverticulosis of intestine, w/o perforation or abscess with bleeding 140 (12.7)
K64.0, K64.1, K64.2, K64.3, K64.9 Hemorrhoids with bleeding 77 (7.0)
K55.22, K55.82 Angiodysplasia of the colon (including small intestine): with Bleeding 62 (5.6)
K57.03, K57.13, K57.21, K57.23, K57.33, K57.43, 
K57.53, K57.93
Diverticulitis of intestine, w/o perforation or abscess with bleeding 34 (3.1)
K62.5 Hemorrhage of anus and rectum 16 (1.5)
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of thromboprophylaxis was increased and significantly out-
weighed that of venous thromboembolism during the hospi-
tal stay. Two-thirds of bleeding events were gastrointestinal 
and were related to gastrointestinal or genitourinary can-
cer. In our study, cancer was independently associated with 
30-day readmissions in both studied populations, UGIB and 
LGIB. This could partly reflect the therapeutic dilemma of 
re-bleeding rates. However, to comprehensively interpret the 
data, it should be noted that we used the ICD-10 classifica-
tion based on Quan and colleagues to define cancer [21]. 
This coding algorithm includes any code to identify solid 
malignant neoplasm, including also tumors of the gastroin-
testinal tract, but not exclusively.
An interesting observation among UGIB patients was 
that those with alcohol use disorder showed a trend toward 
shorter LOS. As other studies found, patients with alcohol 
use disorder tend to leave the hospitals prematurely against 
medical advice [37]. Another issue is that alcohol use 
disorder is a severe and complex comorbidity known for 
unplanned 30-day readmissions and mortality [38]. Many 
patients with alcohol use disorder have chronic liver dis-
ease and, to some degree, coagulopathy (e.g., prolonged pro-
thrombin time) [39]. It is reasonable to assume in the context 
of patients with liver disease and alcohol use disorders, that, 
e.g., the risk of variceal bleeding was increased.
Gastrointestinal bleeding can be a symptom of both, 
chronic and acute disease, in this patient collective. It would 
be interesting to investigate how disease clusters change in 
acute compared with chronic diagnoses and whether this 
has an impact on LOS and 30-day readmissions. In further 
analyses, the drug–drug or drug–disease interactions could 
be considered. Exacerbation of chronic renal failure was 
common in hospitalized older patients with several pre-exist-
ing chronic diseases, while hypertension and atrial fibrilla-
tion significantly clustered with adverse drug events [40]. 
Table 3  Upper GI bleeding (n = 791)
Numbers in bold indicate statistical significance
Adjusted multivariable linear regression model for the outcome 
length of stay and adjusted multivariable logistic regression model for 
the outcome 30-day readmission
95% CI: 95% confidence interval; COPD: Chronic obstructive pulmo-
nary disease
Variable Length of stay 30-day readmis-
sion
Exp (B) (95% CI) OR (95% CI)
Age, per additional year 1.00 (1.00, 1.00) 0.98 (0.96, 0.99)
Male sex 0.96 (0.88, 1.06) 1.03 (0.67, 1.56)
Number of diagnoses, 
per additional diagnosis
1.10 (1.08, 1.11) 1.05 (1.00, 1.10)
Year discharged 0.97 (0.95, 0.99) 1.11 (1.02, 1.20)
Length of stay – – 1.00 (0.97, 1.02)
Alcohol use disorders 0.91 (0.83, 1.00) 1.15 (0.76, 1.74)
Anemia 0.94 (0.82, 1.07) 1.68 (1.00, 2.84)
Atrial fibrillation or 
flutter
1.06 (0.92, 1.23) 1.24 (0.67, 2.28)
Cancer 0.87 (0.76, 0.995) 2.86 (1.68, 4.88)
Chronic kidney disease 0.80 (0.71, 0.91) 1.52 (0.90, 2.56)
Coagulopathy 0.96 (0.85, 1.08) 0.95 (0.57, 1.58)
COPD 1.14 (0.96, 1.35) 1.57 (0.79, 3.11)
Depression 1.12 (0.90, 1.40) 1.06 (0.42, 2.68)
Diabetes 0.85 (0.76, 0.96) 1.41 (0.85, 2.32)
Heart failure 0.91 (0.75, 1.12) 0.61 (0.25, 1.45)
Heart valve disease 0.93 (0.78, 1.12) 1.01 (0.48, 2.15)
Hypertension 0.90 (0.82, 0.996) 1.37 (0.89, 2.10)
Liver disease 1.09 (0.94, 1.28) 0.92 (0.48, 1.77)
Thromboembolic event 1.27 (1.00, 1.61) 1.12 (0.40, 3.12)
Vascular disease 0.80 (0.72, 0.90) 0.94 (0.56, 1.56)
Antithrombotic agents 1.46 (1.32, 1.62) 1.02 (0.65, 1.63)
Table 4  Lower GI bleeding (n = 310)
Numbers in bold indicate statistical significance
Adjusted multivariable linear regression model for the outcome 
length of stay and adjusted multivariable logistic regression model for 
the outcome 30-day readmission
95% CI: 95% confidence interval. COPD: Chronic obstructive pulmo-
nary disease
Variable Length of stay 30-day readmis-
sion
Exp (B) (95% CI) OR (95% CI)
Age, per additional year 1.01 (1.003, 1.01) 0.99 (0.95, 1.02)
Male sex 0.95 (0.83, 1.10) 0.44 (0.20, 0.99)
Number of diagnoses, 
per additional diag-
nosis
1.08 (1.06, 1.10) 1.10 (0.99, 1.22)
Year discharged 0.95 (0.93, 0.98) 1.05 (0.88, 1.24)
Length of stay – – 1.02 (0.97, 1.07)
Alcohol use disorders 1.02 (0.79, 1.31) 2.43 (0.64, 9.27)
Anemia 0.96 (0.79, 1.16) 1.98 (0.77, 5.10)
Atrial fibrillation or 
flutter
0.95 (0.79, 1.14) 2.69 (1.06, 6.82)
Cancer 0.98 (0.74, 1.30) 4.76 (1.40, 16.20)
Chronic kidney disease 1.00 (0.82, 1.22) 1.15 (0.46, 2.91)
Coagulopathy 0.90 (0.76, 1.08) 1.21 (0.50, 2.93)
COPD 0.88 (0.69, 1.12) 0.89 (0.25, 3.25)
Depression 1.03 (0.72, 1.49) 0.52 (0.04, 6.35)
Diabetes 0.87 (0.73, 1.04) 0.82 (0.31, 2.17)
Heart failure 1.13 (0.84, 1.51) 1.01 (0.27, 3.75)
Heart valve disease 0.79 (0.63, 0.995) 0.53 (0.15, 1.79)
Hypertension 0.95 (0.82, 1.11) 0.53 (0.22, 1.25)
Liver disease 0.71 (0.50, 1.01) 0.25 (0.02, 3.15)
Thromboembolic event 0.95 (0.57, 1.57) 1.14 (0.13, 9.94)
Vascular disease 0.79 (0.67, 0.94) 1.62 (0.62, 4.24)
Antithrombotic agents 1.25 (1.07, 1.46) 1.42 (0.50, 4.03)
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Chronic kidney disease was associated with a shorter LOS 
in patients with UGIB in our study. It would be compelling 
to study such outcome analyses with a cluster from chronic 
to acute and acute to chronic diseases. In general, kidney 
disease is a known risk factor for both, UGIB and LGIB 
[41]. However, multimorbidity in the narrower sense is not 
simply the combination of several diseases. The presence 
of multimorbidity results in independent and complex per-
sonal clinical pictures that differ in terms of the character-
istics of the individual components [42]. It appears, though, 
that there are similarities in the clinical picture of GIB. For 
example, more men than women are affected by GIB [25], 
as confirmed in the present study.
Limitations
The findings should be interpreted in the light of the fol-
lowing limitations. This was a single center, retrospective 
study not designed to evaluate causal relationships—we 
therefore report independent associations. The patients were 
not prospectively enrolled for this study and the analyzed 
EHR data were primarily collected for patient management 
purposes and not for research. However, only the physicians 
in charge of the patients were entering the diagnoses into 
the EHR, only over the course of the patients’ stays. After 
the patients were discharged from the hospital, professional 
coders assigned ICD-10 codes to each diagnosis, but they 
neither changed the diagnoses nor their order. A systematic 
review on the accuracy of routinely collected data and dis-
charge coding concluded that “[…] routinely collected data 
are sufficiently robust to support their use for research […]” 
[43]. Further, we did not use scores to capture the severity of 
bleeding, i.e., the need for intervention could not be catego-
rized. Finally, no data on deaths after discharge were avail-
able, which might have contributed to an underestimation of 
the 30-day readmission risk. A major strength of this study is 
the comprehensive and detailed review of the ICD codes that 
defined gastrointestinal bleeding. There is available evidence 
that ICD-10 codes applied to an administrative dataset of 
hospitalized patients appropriately excluded patients with-
out a clinically evident bleeding event [44]. Nevertheless, in 
certain cases, a chart review is necessary, as conducted in 
the present study for the control of diagnoses.
An increasingly recognized risk factor for worse clinical 
outcomes in various patient populations is sarcopenia. In 
the second half of 2016, nearly seven years after the start 
of our study period, Anker et al. published the highly cited 
editorial “Welcome to the ICD-10 code for sarcopenia,” 
[45] additionally supporting the use of routinely collected 
data for epidemiologic research in the context of sarcopenia. 
In fact, a recent study by Lattanzi et al. demonstrated that 
“[…] the rate of refractory variceal bleeding was higher in 
sarcopenic patients, […]” [46] a finding that further encour-
ages the future consideration of sarcopenia as an important 
risk factor also among inpatients, such as those hospitalized 
for the treatment of GIB.
Conclusion
Thromboembolic events in UGIB and atrial fibrillation/flut-
ter in LGIB appear to represent clusters of therapeutic con-
flicts that may negatively impact outcomes in multimorbid 
patients admitted for the treatment of acute GIB. Further 
studies are needed to prospectively investigate the impact of 
these comorbidities, and, importantly, to establish appropri-
ate care and guidelines, especially in patient clusters entail-
ing complex therapeutic conflicts.
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